The clinicopathologic significance of Tks5 expression of peritoneal mesothelial cells in gastric cancer patients.
Adaptor Proteins, Vesicular Transport
/ analysis
Aged
Biomarkers, Tumor
/ analysis
Disease-Free Survival
Epithelial Cells
/ pathology
Female
Follow-Up Studies
Gastrectomy
Humans
Lymphatic Metastasis
Male
Middle Aged
Neoplasm Invasiveness
/ pathology
Peritoneal Neoplasms
/ epidemiology
Peritoneum
/ cytology
Stomach Neoplasms
/ mortality
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
05
01
2021
accepted:
08
06
2021
entrez:
13
7
2021
pubmed:
14
7
2021
medline:
19
11
2021
Statut:
epublish
Résumé
Gastric cancer (GC) patients frequently develop peritoneal metastasis. Recently, it has been reported that peritoneal mesothelial cells (PMCs) activated by GC cells acquire a migratory capacity and promote GC cell invasion. The invasiveness of PMCs reportedly depends on the activity of Tks5, an adaptor protein required for invadopodia formation. However, the relationship between clinicopathologic features and Tks5 expression in PMCs has been poorly documented. In this study, we evaluated the clinicopathologic significance of the Tks5 expression of PMCs in GC patients. A total of 110 GC patients who underwent gastrectomy were enrolled in this study. Tks5 expressions in PMCs from the greater omentum, lesser omentum and retroperitoneum were evaluated by immunohistochemistry. We analyzed the correlation between Tks5 expressions in PMCs and the patients' clinicopathologic features. Tks5 expression was found in 71 (64.5%) of the 110 patients, while 39 (35.5%) were Tks5-negative. Tks5 positivity was significantly (p = 0.038) associated with a greater tumor depth (i.e., T3/4 compared with T1/T2). Peritoneal recurrence was found in 12 of 98 cases within 3 years of surgery. The 3-year peritoneal recurrence-free survival (PRFS) rate in Tks5-positive cases was significantly poorer than that in Tks5-negative cases (80.1% vs 97.4%, p = 0.024). Multivariate analysis revealed that Tks5 positivity and lymph node metastasis were independent factors for PRFS. Tks5 is frequently expressed in PMCs in advanced-stage gastric cancer. Tks5 might be a useful predictor for peritoneal recurrence in GC patients.
Sections du résumé
BACKGROUND
Gastric cancer (GC) patients frequently develop peritoneal metastasis. Recently, it has been reported that peritoneal mesothelial cells (PMCs) activated by GC cells acquire a migratory capacity and promote GC cell invasion. The invasiveness of PMCs reportedly depends on the activity of Tks5, an adaptor protein required for invadopodia formation. However, the relationship between clinicopathologic features and Tks5 expression in PMCs has been poorly documented. In this study, we evaluated the clinicopathologic significance of the Tks5 expression of PMCs in GC patients.
MATERIALS AND METHODS
A total of 110 GC patients who underwent gastrectomy were enrolled in this study. Tks5 expressions in PMCs from the greater omentum, lesser omentum and retroperitoneum were evaluated by immunohistochemistry. We analyzed the correlation between Tks5 expressions in PMCs and the patients' clinicopathologic features.
RESULTS
Tks5 expression was found in 71 (64.5%) of the 110 patients, while 39 (35.5%) were Tks5-negative. Tks5 positivity was significantly (p = 0.038) associated with a greater tumor depth (i.e., T3/4 compared with T1/T2). Peritoneal recurrence was found in 12 of 98 cases within 3 years of surgery. The 3-year peritoneal recurrence-free survival (PRFS) rate in Tks5-positive cases was significantly poorer than that in Tks5-negative cases (80.1% vs 97.4%, p = 0.024). Multivariate analysis revealed that Tks5 positivity and lymph node metastasis were independent factors for PRFS.
CONCLUSION
Tks5 is frequently expressed in PMCs in advanced-stage gastric cancer. Tks5 might be a useful predictor for peritoneal recurrence in GC patients.
Identifiants
pubmed: 34255789
doi: 10.1371/journal.pone.0253702
pii: PONE-D-21-00313
pmc: PMC8277061
doi:
Substances chimiques
Adaptor Proteins, Vesicular Transport
0
Biomarkers, Tumor
0
SH3PXD2A protein, human
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0253702Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Eur J Cell Biol. 2008 Sep;87(8-9):555-67
pubmed: 18417249
Cancers (Basel). 2015 Sep 29;7(4):1994-2011
pubmed: 26426054
World J Gastroenterol. 2013 Nov 7;19(41):6979-94
pubmed: 24222942
J Cell Sci. 2018 Jan 8;131(1):
pubmed: 29311151
Cancer. 2000 Jan 15;88(2):358-63
pubmed: 10640968
Cancer Microenviron. 2010 Jan 26;3(1):127-35
pubmed: 21209779
Cancer Cell. 2005 Feb;7(2):155-65
pubmed: 15710328
Int J Oncol. 1998 Apr;12(4):847-51
pubmed: 9499445
Oncotarget. 2016 Nov 29;7(48):78473-78486
pubmed: 27802184
PLoS One. 2020 Jan 15;15(1):e0225958
pubmed: 31940352
Br J Cancer. 1996 Nov;74(9):1406-12
pubmed: 8912536
Oncotarget. 2015 Sep 29;6(29):27083-96
pubmed: 26334100
Cancer Res. 2017 Feb 1;77(3):684-695
pubmed: 27895076
Lancet. 2009 Aug 8;374(9688):477-90
pubmed: 19625077
Fertil Steril. 2016 Oct;106(5):1018-1024
pubmed: 27692285
World J Gastroenterol. 2016 Aug 14;22(30):6829-40
pubmed: 27570420
J Cell Sci. 2019 Oct 18;132(20):
pubmed: 31533971
Oncotarget. 2017 Jun 27;8(26):43481-43490
pubmed: 28415645
PLoS One. 2015 Mar 31;10(3):e0121003
pubmed: 25826475
Oncol Rep. 2014 Sep;32(3):989-1002
pubmed: 24993883
PLoS One. 2017 Aug 2;12(8):e0181579
pubmed: 28767724
Lancet Oncol. 2013 Nov;14(12):e535-47
pubmed: 24176572
Int J Biochem Cell Biol. 2004 Jan;36(1):9-16
pubmed: 14592528
Prostate. 2014 Feb;74(2):134-48
pubmed: 24174371
Br J Cancer. 2011 Sep 27;105(7):996-1001
pubmed: 21863023
Oncogene. 2015 Jun 11;34(24):3176-87
pubmed: 25088196
Cell Mol Life Sci. 2018 Feb;75(3):509-525
pubmed: 28956065
Cell Rep. 2014 Sep 11;8(5):1558-70
pubmed: 25176655